angiotensin converting enzyme inhibitors (ACEI)
DISEASE INTERVENTION COMPARISON RESULTS
J Card Fail. 2010 Mar;16(3):260-7 Meta-Analysis
IN heart failure, chronic, diastolic (preserved ejection fraction) The Use of
renin-angiotensin system inhibitors, angiotensin converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB)
As Treatment, Chronic
Is equal Than
placebo
To reduce hospitalizations for heart failure or all-cause mortality.
Heart. 2017 Aug 5. pii: heartjnl-2017-311652. doi: 10.1136/heartjnl-2017-311652. [Epub ahead of prin Meta-Analysis
IN heart failure, chronic, diastolic (preserved ejection fraction) The Use of
various medical treatments: angiotensin converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB), beta blockers, aldosterone blockers, spironolactone
As Treatment, Chronic
Is equal Than
placebo
To modify survival (except beta blockers, associated with reduced all-cause and cardiac deaths, (RR: 0.78) or reduce rehospitalizations or improve functional capacity
Heart. 2017 Aug 5. doi: 10.1136/heartjnl-2017-311652. [Epub ahead of prin Systematic Review
IN heart failure, chronic, diastolic (preserved ejection fraction) The Use of
various medical treatments: angiotensin converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB), beta blockers, others
As Treatment, Chronic
Is equal Than
placebo ou usual care without those treatments
To modify mortality, with the exception of beta-blockers (RR 0.78). Trend to improve, but non consistent results, exercise capacity and quality of life
J Am Coll Cardiol. 2011 Apr 19;57(16):1676-86 Meta-Analysis
IN heart failure, chronic, diastolic (preserved ejection fraction) The Use of
various medical treatments: angiotensin converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB), beta blockers, others
As Treatment, Chronic
Is better Than
placebo ou usual care without those treatments
To improve excercise tolerance (51 to 61 more seconds on treadmill excercise test) but not heart fonction (E/A ratio) nor mortality
Eur Heart J. 2006 Oct;27(19):2338-45 Randomized Controlled Trial, Multicenter Study
IN heart failure, chronic, diastolic (preserved ejection fraction), elder patients The Use of
angiotensin converting enzyme inhibitors (ACEI), perindopril
As Treatment, Chronic
Is better Than
placebo
To reduce at 1 year hospitalizations for heart failure (HR 0.63) and improve functional class. However, differences in primary combined outcome at 2 years were not significant
Eur Heart J. 2012 Aug;33(16):2088-97 Meta-Analysis
IN hypertension, primary The Use of
angiotensin converting enzyme inhibitors (ACEI)
As Treatment, Chronic
Is better Than
placebo, and probably better than angiotensin II receptor blockers (ARBs)
To reduce all-cause mortality (20.4 deaths per 1000 patient-years with ACEIs VS 24.2 placebo). No significant mortality reduction appeared with ARB treatment
Cochrane Database Syst Rev. 2009;(3):CD001841 Systematic Review, Cochrane Review
IN hypertension, primary The Use of
low-dose thiazide diuretics, angiotensin converting enzyme inhibitors (ACEI), and possibly calcium channel blockers
As Treatment, Chronic
Is better Than
high-dose thiazide diuretics, beta blockers
To reduce mortality, strokes and cardiovascular events
N Engl J Med. 2008 May 1;358(18):1887-98 Randomized Controlled Trial, Multicenter Study
IN hypertension, primary, elder patients The Use of
diuretic, indapamide, plus, if needed, angiotensin converting enzyme inhibitors (ACEI), perindopril
As Treatment, Chronic
Is better Than
placebo
To reduce mortality, cardiovascular mortality and stroke (absolute risk reduction not reported in abstract)
Ann Intern Med. 2001 Jul 17;135(2):73-87 Meta-Analysis
IN kidney disease, chronic, non diabetic The Use of
angiotensin converting enzyme inhibitors (ACEI)
As Treatment, Chronic
Is better Than
antihypertensive regimens not including ACEI
To reduce progression to end-stage renal failure (RR 0.7). The higher the uninary protein excrection, the higher the benefit.
Lancet. 1999 Jul 31;354(9176):359-64 Randomized Controlled Trial
IN kidney disease, chronic, non diabetic The Use of
angiotensin converting enzyme inhibitors (ACEI), ramipril
As Treatment, Chronic
Is better Than
placebo plus conventional antihypertensive therapy
To reduce progression to end-stage renal failure: 9% ACEI VS 20% controls